Oncotelic Therapeutics

OTLC · OTC

$0.0176−$0.0009 (−4.86%)TodayMarket closed · Oct 20, 3:55 PM ET

Prev close $0.0185

Latest news

Press releaseOct 20, 8:00 AM ETGlobe Newswire
Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery
Press releaseOct 5, 8:00 AM ETGlobe Newswire
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
Press releaseJul 22, 9:30 AM ETGlobe Newswire
Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
Press releaseJul 7, 9:30 AM ETGlobe Newswire
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Press releaseJun 29, 8:30 AM ETGlobe Newswire
Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
Press releaseJun 18, 8:00 AM ETGlobe Newswire
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
Press releaseJun 17, 8:30 AM ETGlobe Newswire
TechForce Robotics Advances Pharmaceutical Automation Initiative Through Phase 2 Deployment of PUR-E at SAPU Bio OEB-5 Sterile Injectable cGMP Facility
Press releaseJun 17, 8:00 AM ETGlobe Newswire
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
Press releaseJun 8, 8:00 AM ETGlobe Newswire
Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote
Press releaseJun 5, 8:30 AM ETGlobe Newswire
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies
Press releaseJun 4, 8:30 AM ETGlobe Newswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
Press releaseJun 3, 8:30 AM ETGlobe Newswire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Press releaseJun 2, 8:30 AM ETGlobe Newswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
Press releaseJun 1, 8:30 AM ETGlobe Newswire
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
Press releaseMay 15, 8:30 AM ETGlobe Newswire
NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations
Press releaseMay 14, 8:30 AM ETGlobe Newswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
Press releaseMay 13, 8:30 AM ETGlobe Newswire
CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
Press releaseMay 12, 8:30 AM ETGlobe Newswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
Press releaseMay 11, 8:30 AM ETGlobe Newswire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Press releaseApr 24, 8:30 AM ETGlobe Newswire
NetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development Pathways
Press releaseApr 23, 8:30 AM ETGlobe Newswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation
Press releaseApr 22, 8:30 AM ETGlobe Newswire
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
Press releaseApr 21, 8:30 AM ETGlobe Newswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution
Press releaseApr 20, 8:30 AM ETGlobe Newswire
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
Press releaseApr 10, 8:30 AM ETGlobe Newswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space
Press releaseApr 9, 8:30 AM ETGlobe Newswire
AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
Press releaseApr 8, 8:30 AM ETGlobe Newswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Operates at Intersection of Life Sciences, Advanced Digital Technologies,
Press releaseApr 7, 8:30 AM ETGlobe Newswire
AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards
Press releaseFeb 23, 8:30 AM ETGlobe Newswire
NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios
Press releaseFeb 20, 8:30 AM ETGlobe Newswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution
Press releaseFeb 19, 8:30 AM ETGlobe Newswire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
Press releaseFeb 18, 8:30 AM ETGlobe Newswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset Trend
Press releaseFeb 17, 8:30 AM ETGlobe Newswire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Press releaseDec 15, 10:00 AM ETGlobe Newswire
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer
Press releaseDec 4, 10:00 AM ETGlobe Newswire
Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine
Press releaseDec 3, 9:00 AM ETGlobe Newswire
Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing
Press releaseDec 2, 8:00 AM ETGlobe Newswire
Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs
Press releaseNov 25, 8:30 AM ETGlobe Newswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation
Press releaseOct 30, 6:00 AM ETGlobe Newswire
Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)
Press releaseOct 23, 8:00 AM ETGlobe Newswire
Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)
Press releaseOct 20, 8:00 AM ETGlobe Newswire
Oncotelic to Present at the LD Micro Main Event XIX
Press releaseApr 16, 9:15 AM ETGlobe Newswire
Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery

PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026

Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)

Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway

Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003

Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026

TechForce Robotics Advances Pharmaceutical Automation Initiative Through Phase 2 Deployment of PUR-E at SAPU Bio OEB-5 Sterile Injectable cGMP Facility

Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services

Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote

NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure

How Advanced Drug Delivery Could Improve Existing Cancer Treatments

NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform

CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities

NetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development Pathways

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space

AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Operates at Intersection of Life Sciences, Advanced Digital Technologies,

AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards

NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset Trend

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer

Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing

Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation

Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

Oncotelic to Present at the LD Micro Main Event XIX

Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023